Publications

BibTex format

@article{Cheng:2018:10.1097/FPC.0000000000000334,
author = {Cheng, H and Yan, D and Zuo, X and Liu, J and Liu, W and Zhang, Y},
doi = {10.1097/FPC.0000000000000334},
journal = {Pharmacogenetics and Genomics},
pages = {117--124},
title = {A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China},
url = {http://dx.doi.org/10.1097/FPC.0000000000000334},
volume = {28},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy but it has severe side-effects.  HLA-B5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. In this retrospective report, we had genotyped HLA-B5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications. We found 30 carriers of HLA-B5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B5801 positive and negative groups.  The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated the HLA-B5801 screening had significant cost benefit for clinical management. HLA-B5801 allele should be screened in all patients with hyperuiciemia and gout in the Chinese population.
AU  - Cheng,H
AU  - Yan,D
AU  - Zuo,X
AU  - Liu,J
AU  - Liu,W
AU  - Zhang,Y
DO  - 10.1097/FPC.0000000000000334
EP  - 124
PY  - 2018///
SN  - 1744-6872
SP  - 117
TI  - A retrospective investigation of HLA-B5801 in hyperuricemia patients in a Han population of China
T2  - Pharmacogenetics and Genomics
UR  - http://dx.doi.org/10.1097/FPC.0000000000000334
UR  - http://hdl.handle.net/10044/1/58036
VL  - 28
ER  -

Download

DrYoumingZhang

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)